An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Brain metastases
- Focus Diagnostic use
- Acronyms PURSUE
- Sponsors Blue Earth Diagnostics
Most Recent Events
- 06 Jun 2023 Results assessing diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 20 Dec 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2022 According to a Blue Earth Diagnostics media release, results from this study will be presented at the upcoming scientific meetings later this year.